The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...

The conference’s final presidential session this afternoon focused on studies that touch on the burgeoning issues oncology ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Natera has released new data from the GALAXY arm of its ongoing CIRCULATE-Japan trial showing the efficacy of its molecular ...

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and ...

The ESMO Congress 2024 will showcase a wealth of new oncology data, highlighting the pace of innovation in cancer treatment.

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...